Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib Plus Chemotherapy as Neoadjuvant Treatment of HER2-Negative Breast Cancer
NCT05558722Phase 2Active, not recruiting
- Sponsor
- Xijing Hospital
- Start
- Dec 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in breast cancer, sponsored by Xijing Hospital. Started Dec 2022; status: active, not recruiting.
02
Drugs
anlotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05558722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05558722.